We are live on ! Find out more
IHE icon

iShares US Pharmaceuticals ETF

102 hedge funds and large institutions have $321M invested in iShares US Pharmaceuticals ETF in 2015 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 43 increasing their positions, 32 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

34% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 32

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

8.04% less ownership

Funds ownership: 104.24%96.2% (-8%)

15% less funds holding

Funds holding: 120102 (-18)

21% less capital invested

Capital invested by funds: $404M → $321M (-$83M)

74% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 23

Holders
102
Holders Change
-18
Holders Change %
-15%
% of All Funds
2.85%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.11%
New
6
Increased
43
Reduced
32
Closed
23
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
PAG
51
Pinnacle Advisory Group
Maryland
$508K -$293K -5,115 -33%
CLOS
52
Compagnie Lombard Odier SCmA
Switzerland
$506K +$46.4K +810 +9%
HSBC Holdings
53
HSBC Holdings
United Kingdom
$503K
ASN
54
Advisory Services Network
Georgia
$480K +$27.2K +474 +5%
LSA
55
L & S Advisors
California
$445K +$46.4K +810 +10%
CS
56
Credit Suisse
Switzerland
$430K -$2.28M -39,840 -82%
BCM
57
Beck Capital Management
Texas
$429K +$495K +8,640 New
Creative Planning
58
Creative Planning
Kansas
$417K +$484K +8,448 New
CCM
59
Condor Capital Management
New Jersey
$410K -$688 -12 -0.1%
JMPWA
60
JP Morgan Private Wealth Advisors
California
$405K +$133K +2,325 +39%
BI
61
Boulegeris Investments
Georgia
$396K +$94.6K +1,650 +26%
CB
62
Commerce Bank
Missouri
$383K
Cambridge Investment Research Advisors
63
Cambridge Investment Research Advisors
Iowa
$377K -$155K -2,700 -26%
BTS
64
BB&T Securities
Virginia
$374K +$210K +3,666 +93%
SI
65
Stephens Inc
Arkansas
$368K +$26.7K +465 +7%
BA
66
Boston Advisors
Massachusetts
$346K +$402K +7,011 New
DC
67
Davenport & Co
Virginia
$345K -$91.1K -1,590 -19%
Janney Montgomery Scott
68
Janney Montgomery Scott
Pennsylvania
$344K -$76.5K -1,335 -16%
PAG
69
Private Advisor Group
New Jersey
$339K -$98.9K -1,725 -20%
FAAS
70
First Allied Advisory Services
California
$337K -$50.4K -879 -11%
CWM
71
Concert Wealth Management
California
$300K +$46.3K +807 +15%
Millennium Management
72
Millennium Management
New York
$291K -$118K -2,055 -26%
BFS
73
Bradley Foster & Sargent
Connecticut
$266K
SPC
74
Sigma Planning Corp
Michigan
$255K -$1.11M -19,419 -79%
FANJ
75
Financial Architects (New Jersey)
New Jersey
$255K +$155K +2,712 +110%

IHE Hedge Fund Activity: Q3 2015 in Review

102 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q3 2015, worth a combined $321M — down 21% from $404M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of IHE and 6 opened new positions — a net loss of 17 holders — while 32 trimmed existing stakes and 43 added.

The largest buyer was Susquehanna International Group, adding an estimated $5.8M. The largest seller was Morgan Stanley, cutting an estimated $19.8M.

  • 102 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q3 2015, down from 120 in Q2 2015.
  • Funds reported $321M of iShares US Pharmaceuticals ETF stock for Q3 2015, down 21% quarter-over-quarter.
  • 6 funds opened new iShares US Pharmaceuticals ETF positions in Q3 2015 and 23 closed out, a net change of -17 holders.
  • The largest iShares US Pharmaceuticals ETF buyer in Q3 2015 was Susquehanna International Group, an estimated $5.8M added.
  • The largest iShares US Pharmaceuticals ETF seller in Q3 2015 was Morgan Stanley, an estimated $19.8M sold.

Based on aggregated 13F filings for Q3 2015.